Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Oct 21;30(39):4318-4323.
doi: 10.3748/wjg.v30.i39.4318.

Advances in the research of intestinal fungi in Crohn's disease

Affiliations
Editorial

Advances in the research of intestinal fungi in Crohn's disease

Mo-Wei Kong et al. World J Gastroenterol. .

Abstract

This article reviews of the original research published by Wu et al in the World Journal of Gastroenterology, delving into the pivotal role of the gut microbiota in the pathogenesis of Crohn's disease (CD). Insights were gained from fecal microbiota transplantation (FMT) in mouse models, revealing the intricate interplay between the gut microbiota, mesenteric adipose tissue (MAT), and creeping fat. The study uncovered the characteristics of inflammation and fibrosis in the MAT and intestinal tissues of patients with CD; moreover, through the FMT mouse model, it observed the impact of samples from healthy patients and those with CD on symptoms. The pathogenesis of CD is complex, and its etiology remains unclear; however, it is widely believed that gut microbiota dysbiosis plays a significant role. Recently, with the development and application of next-generation sequencing technology, research on the role of fungi in the pathogenesis and chronicity of CD has deepened. This editorial serves as a supplement to the research by Wu et al who discussed advances related to the study of fungi in CD.

Keywords: Crohn's disease pathogenesis; Fecal microbiota transplantation; Gut fungal dynamics; Intestinal microbiota; Mesenteric adipose tissue.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare that they have no competing interests.

Similar articles

Cited by

References

    1. Wu Q, Yuan LW, Yang LC, Zhang YW, Yao HC, Peng LX, Yao BJ, Jiang ZX. Role of gut microbiota in Crohn's disease pathogenesis: Insights from fecal microbiota transplantation in mouse model. World J Gastroenterol. 2024;30:3689–3704. - PMC - PubMed
    1. Chen L, Su C, Ding H, Mei Q. Small molecules for inflammatory bowel disease and the risk of infection and malignancy: A systematic review and meta-Analysis. Dig Liver Dis. 2024 - PubMed
    1. Xu C, Kadosh D, Sun D, Zeng G, Gao YZ. Editorial: Omics-originated exploration of pathogenic patterns and molecular mechanisms in human and animal fungal pathogens. Front Microbiol. 2023;14:1243709. - PMC - PubMed
    1. Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr INSPIRE and COMMAND Study Group. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. JAMA. 2024;332:881–897. - PMC - PubMed
    1. Subramanian A, Jahabardeen A, Thamaraikani T, Vellapandian C. More on the interplay between gut microbiota, autophagy, and inflammatory bowel disease is needed. World J Gastroenterol. 2024;30:3356–3360. - PMC - PubMed

Publication types